Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFD Technologies Regulatory News (FDP)

  • This share is currently suspended. It was suspended at a price of 2,450.00
  • There is currently no data for FDP

Trading Statement

25 Mar 2025 07:00

RNS Number : 9472B
FD Technologies PLC
25 March 2025
 

FD Technologies plc

Trading update for the 12 months ended 28 February 2025

25th March 2025

Strong FY25 performance with annual contract value ("ACV") at top end of guidance range and cash EBITDA above top end of consensus expectations

 

FY251

FY24

YoY (+/-)

£ million

Expected

Expected

ARR2

81.8

72.5

+13%

ACV3 added

18.0

13.5

+33%

Cash EBITDA4

(14.6)

(18.8)

NM

 

§

KX continued to execute well in the second half of the year, delivering FY bookings growth at the top end of our guidance range and ahead of consensus** expectations, with £18.0 million annual ACV (FY24: £13.5 million), +33 per cent YoY.

§

KX achieved a significant milestone, with annual recurring revenue exceeding $100 million* for the first time, after constant currency growth of 13 per cent to £81.8 million (FY24: £72.5 million), in line with the guidance range.

§

Cash EBITDA was ahead of guidance and above the top end of consensus expectations with a loss of £14.6 million (FY24: loss of £18.8 million).

§

Proven use cases are driving the adoption of KDB.AI, which facilitates real-time AI-powered research assistance, anomaly detection, predictive analytics in capital markets, and satellite imagery analysis and signal processing in aerospace and defence.

§

Market demand for time-series AI is growing as industries shift towards real-time, context-aware AI. KDB.AI's ability to seamlessly combine historical and real-time data with low-latency AI processing sets it apart as a category leader.

§

Following the divestment of MRP (retaining a 49 per cent associate investment in the resulting merged entity, PharosIQ) and First Derivative, we returned £120 million to shareholders and KX closed the year with £56 million net cash and no debt.

§

We enter FY26 with a strong and growing pipeline of expansion and new opportunities across capital markets, aerospace and defence, and industrial IoT. This gives us confidence at this early stage in the year that we can achieve FY26 ARR growth of at least 20%.

Seamus Keating, Group CEO of FD Technologies, commented:

"We made significant strategic and operational progress in FY25. With accelerating ARR growth and better-than-expected operating leverage, KX delivered a strong performance based on good ongoing execution. We restructured our business to focus solely on KX, returned £120 million of value to shareholders, and ensured that KX is well capitalised to execute its strategy for growth and profitability."

Ashok Reddy, CEO of KX, added:

"The strong bookings growth in the period demonstrates that our strategy is working and reflects the benefits of our investments to enhance our go-to-market operations and simplify adoption. We enter FY26 with a strong and growing pipeline of expansion and new opportunities across capital markets, aerospace and defence, and industrial IoT, and view the outlook for the year with confidence."

* £81.8 million ARR restated in US dollars was $103.1 million, using the US$/£ exchange rate of 1.26 on 28 February 2025.

** On 28 February 2025, the company-compiled analyst mean consensus estimates indicated £16.7 million in ACV added during the period (range £16.0-17.0 million), £82.8 million in ARR (range £81.2-84.5 million), and an £18.5 million Cash EBITDA loss (range of £16.3-20.1 million loss). The consensus included estimates from six analysts.

 

1 All figures are only for KX's continuing operations and exclude the divested First Derivative business.

2 Annual recurring revenue: the total value of recurring software revenue expected to be recognised over the next 12 months, on the final day of the reporting period.

3 Annual contract value: the sum of the value of each customer contract signed during the year divided by the number of years in each contract.

4 Earnings before interest, tax, depreciation and amortisation adjusted to exclude share-based payments, capitalised R&D, and exceptional items.

 

Contacts

 

FD Technologies plc

Seamus Keating, Chief Executive Officer

Ryan Preston, Chief Financial Officer

Derek Brown, SVP Investor Relations

 

www.fdtechnologies.com

investors@kx.com

Investec Bank plc - Nominated Adviser and Broker

Carlton Nelson

Virginia Bull

+44 (0)20 7597 5970

Goodbody - Euronext Growth Adviser and Broker

Don Harrington

Jason Molins

Tom Nicholson

+353 1 667 0420

 

J.P. Morgan Cazenove - Broker

James A. Kelly

Mose Adigun

+44 (0)20 3493 8000

 

FTI Consulting - Financial PR

Matt Dixon

Dwight Burden

Victoria Caton

+44 (0)20 3727 1000

fdtechnologies@fticonsulting.com

 

About KX

KX is on a mission to make AI a commercial reality for the many by addressing data challenges that impede deployment at scale. By simultaneously ingesting and analysing high volumes of historical and real-time data, KX's AI-ready analytical database enables organizations to unlock the full value of their data to accelerate innovation and make faster, more confident decisions.

 

KX is the world's most performant, cost-effective and energy-efficient analytical database, delivering advanced data algorithms, insights and analytics at unmatched scale and speed. KX is trusted by the world's top investment banks, Aerospace and Defence, high-tech manufacturing and health and life sciences organisations and operates across North America, Europe, and Asia Pacific.

 

For further information, please visit www.fdtechnologies.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRGDXBDDDGUS
Date   Source Headline
1st Sep 20091:24 pmRNSExercise of Options
3rd Aug 20094:40 pmRNSDirector/PDMR Shareholding
22nd Jul 20092:42 pmRNSDirector/PDMR Shareholding
23rd Jun 20095:00 pmRNSPassing of AGM Resolutions
23rd Jun 20097:00 amRNSAGM Statement
20th May 200912:50 pmRNSDividend Declaration
20th May 20097:00 amRNSDirectorate Change
20th May 20097:00 amRNSFinal Results
24th Apr 20094:45 pmRNSDirector Declaration
1st Apr 20097:00 amRNSAcquisition
31st Mar 20093:12 pmRNSTotal Voting Rights
31st Mar 20097:00 amRNSIEX Notice
25th Mar 20092:47 pmRNSIssue of Equity
30th Jan 20094:20 pmRNSTotal Voting Rights
29th Jan 200910:07 amRNSNew Investment - Replacement
29th Jan 20099:00 amRNSFinancial Support from Invest NI
26th Jan 20097:00 amRNSOEM License Agreement
23rd Jan 20093:45 pmRNSDirector/PDMR Shareholding
16th Jan 20097:00 amRNSDirectorate Change
9th Jan 20094:11 pmRNSExercise of Options
23rd Oct 20087:30 amRNSNon Regulatory Announcement
9th Oct 20087:00 amRNSInterim Results
30th Sep 20082:23 pmRNSTotal Voting Rights
30th Sep 20087:00 amRNSIssue of Equity
15th Sep 20087:00 amRNSAcquisition
28th Aug 20083:02 pmRNSAnnual Report and Accounts
27th Aug 20087:00 amRNSDirectorate Change
13th Aug 20087:00 amRNSIEX Notice
7th Aug 20084:47 pmRNSIssue of Equity
9th Jul 20087:00 amRNSRe Contract
17th Jun 200812:40 pmRNSAGM Statement
14th May 20087:00 amRNSDirectorate Change
14th May 20087:00 amRNSFinal Results
7th May 20084:22 pmRNSNotice of Results
30th Apr 20081:39 pmRNSTotal Voting Rights
29th Feb 20082:41 pmRNSIssue of Equity
28th Feb 20087:00 amRNSTrading Statement
1st Feb 20084:17 pmRNSResult of EGM
30th Nov 200711:33 amRNSTotal Voting Rights
21st Nov 20075:01 pmRNSDirector/PDMR Shareholding
14th Nov 20071:17 pmRNSIssue of Equity
9th Nov 20074:45 pmRNSDirector/PDMR Shareholding
9th Nov 20074:42 pmRNSDirector/PDMR Shareholding
1st Nov 200710:33 amRNSTotal Voting Rights
4th Oct 20075:27 pmRNSInterim Results - Replacement
4th Oct 20077:01 amRNSInterim Results
28th Sep 20073:01 pmRNSChange of Adviser
23rd Aug 20077:00 amRNSTrading Statement
23rd Aug 20077:00 amRNSTrading Statement
17th Aug 20075:01 pmRNSWebsite Information

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.